<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="interaction" /><meta name="keywords" content="" /><title>Dosulepin: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="bnf_int245-dosulepin.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="bnf_int245-dosulepin.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=bnf_int245-dosulepin.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 07 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP8848-interactions.htm">Appendix 1 Interactions</a> &gt; <a href="PHP8852-list-of-drug-interactions.htm">List of drug interactions</a> &gt; <a href="bnf_int229-antidepressants.htm">Antidepressants</a> &gt; <a href="bnf_int241-antidepressants-tricyclic.htm">Antidepressants, Tricyclic</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="bnf_int244-clomipramine.htm" title="Previous: Clomipramine">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="bnf_int246-doxepin.htm" title="Next: Doxepin">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1>Dosulepin</h1><?highlighter on?><div id="pC" class="jN"><p><strong>Dosulepin</strong> has no specific interaction information.</p><p><strong>Dosulepin</strong> belongs to <strong>Antidepressants, Tricyclic</strong> and will have the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int715-adrenaline-epinephrine.htm">Adrenaline (epinephrine)</a></td><td class="cAI"><p><span>increased risk of hypertension and arrhythmias when </span> <span>tricyclics</span> <span>given with</span> <span>adrenaline (epinephrine)</span> <span>(but local anaesthetics with adrenaline appear to be safe)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int15-adrenergic-neurone-blockers.htm">Adrenergic Neurone Blockers</a></td><td><p><span></span> <span>tricyclics</span> <span>antagonise hypotensive effect of</span> <span>adrenergic neurone blockers</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int20-alcohol.htm">Alcohol</a></td><td class="cAI"><p><span>increased sedative effect when </span> <span>tricyclics</span> <span>given with</span> <span>alcohol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int118-amiodarone.htm">Amiodarone</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>tricyclics</span> <span>given with</span> <span>amiodarone</span> <span>—avoid concomitant use</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</p></div></td></tr><tr><td><a href="bnf_int39-anaesthetics-general.htm">Anaesthetics, General</a></td><td><p><span>increased risk of arrhythmias and hypotension when </span> <span>tricyclics</span> <span>given with</span> <span>general anaesthetics</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> See also Surgery and Long-term Medication, 
<a title="target-block: surgery and long term med" href="PHP8495-general-anaesthesia.htm#PHP8498">section 15.1</a>



</p></div></td></tr><tr><td><a href="bnf_int232-antidepressants-ssri.htm">Antidepressants, SSRI</a></td><td class="cAI"><p><span>plasma concentration of some </span> <span>tricyclics</span> <span>increased by</span> <span>SSRIs</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int276-antiepileptics.htm">Antiepileptics</a></td><td class="cAI"><p><span></span> <span>tricyclics</span> <span>antagonise anticonvulsant effect of</span> <span>antiepileptics</span> <span>(convulsive threshold lowered)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int303-antihistamines.htm">Antihistamines</a></td><td><p><span>increased antimuscarinic and sedative effects when </span> <span>tricyclics</span> <span>given with</span> <span>antihistamines</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Sedative interactions apply to a lesser extent to the non-sedating antihistamines. Interactions do not generally apply to antihistamines used for topical action (including inhalation)</p></div></td></tr><tr><td><a href="bnf_int342-antimuscarinics.htm">Antimuscarinics</a></td><td><p><span>increased risk of antimuscarinic side-effects when </span> <span>tricyclics</span> <span>given with</span> <span>antimuscarinics</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Many drugs have antimuscarinic effects; concomitant use of two or more such drugs can increase side-effects such as dry mouth, urine retention, and constipation; concomitant use can also lead to confusion in the elderly. Interactions do not generally apply to antimuscarinics used by inhalation</p></div></td></tr><tr><td><a href="bnf_int363-antipsychotics.htm">Antipsychotics</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>tricyclics</span> <span>increased by</span> <span>antipsychotics</span> <span>—possibly increased risk of ventricular arrhythmias</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with myelosuppressive drugs</p></div></td></tr><tr><td><a href="bnf_int404-anxiolytics-and-hypnotics.htm">Anxiolytics and Hypnotics</a></td><td><p><span>increased sedative effect when </span> <span>tricyclics</span> <span>given with</span> <span>anxiolytics and hypnotics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int24-apraclonidine.htm">Apraclonidine</a></td><td><p><span>avoidance of </span> <span>tricyclics</span> <span>advised by manufacturer of</span> <span>apraclonidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1009-atomoxetine.htm">Atomoxetine</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>tricyclics</span> <span>given with</span> <span>atomoxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int617-baclofen.htm">Baclofen</a></td><td><p><span></span> <span>tricyclics</span> <span>enhance muscle relaxant effect of</span> <span>baclofen</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int25-brimonidine.htm">Brimonidine</a></td><td><p><span>avoidance of </span> <span>tricyclics</span> <span>advised by manufacturer of</span> <span>brimonidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int896-bupropion.htm">Bupropion</a></td><td><p><span>plasma concentration of </span> <span>tricyclics</span> <span>possibly increased by</span> <span>bupropion</span> <span>(possible increased risk of convulsions)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1189-cannabis-extract.htm">Cannabis Extract</a></td><td><p><span>possible increased risk of hypertension and tachycardia when </span> <span>tricyclics</span> <span>given with</span> <span>cannabis extract</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span>metabolism of </span> <span>tricyclics</span> <span>accelerated by</span> <span>carbamazepine</span> <span>(reduced plasma concentration and reduced effect)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td><p><span>plasma concentration of </span> <span>tricyclics</span> <span>possibly increased by</span> <span>cimetidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int482-clonidine.htm">Clonidine</a></td><td class="cAI"><p><span></span> <span>tricyclics</span> <span>antagonise hypotensive effect of</span> <span>clonidine</span> <span>, also increased risk of hypertension on <span>clonidine</span> withdrawal</span>  </p></td><td></td></tr><tr><td><a href="bnf_int364-clozapine.htm">Clozapine</a></td><td><p><span>possible increased antimuscarinic side-effects when </span> <span>tricyclics</span> <span>given with</span> <span>clozapine</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</p></div></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>tricyclics</span> <span>may enhance or reduce anticoagulant effect of</span> <span>coumarins</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int468-diltiazem.htm">Diltiazem</a></td><td><p><span>plasma concentration of </span> <span>tricyclics</span> <span>possibly increased by</span> <span>diltiazem</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int119-disopyramide.htm">Disopyramide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>tricyclics</span> <span>given with</span> <span>disopyramide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int523-disulfiram.htm">Disulfiram</a></td><td><p><span>metabolism of </span> <span>tricyclics</span> <span>inhibited by</span> <span>disulfiram</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int524-diuretics.htm">Diuretics</a></td><td><p><span>increased risk of postural hypotension when </span> <span>tricyclics</span> <span>given with</span> <span>diuretics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1176-dronedarone.htm">Dronedarone</a></td><td class="cAI"><p><span>avoidance of </span> <span>tricyclics</span> <span>advised by manufacturer of</span> <span>dronedarone</span> <span>(risk of ventricular arrhythmias)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1152-droperidol.htm">Droperidol</a></td><td class="cAI"><p><span>avoidance of </span> <span>tricyclics</span> <span>advised by manufacturer of</span> <span>droperidol</span> <span>(risk of ventricular arrhythmias)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int854-entacapone.htm">Entacapone</a></td><td><p><span>caution with </span> <span>tricyclics</span> <span>advised by manufacturer of</span> <span>entacapone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int120-flecainide.htm">Flecainide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>tricyclics</span> <span>given with</span> <span>flecainide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1180-histamine.htm">Histamine</a></td><td><p><span></span> <span>tricyclics</span> <span>theoretically antagonise effects of</span> <span>histamine</span> <span>—manufacturer of <span>histamine</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int372-lithium.htm">Lithium</a></td><td><p><span>risk of toxicity when </span> <span>tricyclics</span> <span>given with</span> <span>lithium</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td class="cAI"><p><span>increased risk of hypertension and CNS excitation when </span> <span>tricyclics</span> <span>given with</span> <span>MAOIs</span> <span>, <span>tricyclics</span> should not be started until 2 weeks after stopping <span>MAOIs</span> (3 weeks if starting clomipramine or imipramine), also <span>MAOIs</span> should not be started for at least 1–2 weeks after stopping <span>tricyclics</span> (3 weeks in the case of clomipramine or imipramine)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int718-methylphenidate.htm">Methylphenidate</a></td><td><p><span>metabolism of </span> <span>tricyclics</span> <span>possibly inhibited by</span> <span>methylphenidate</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int262-moclobemide.htm">Moclobemide</a></td><td class="cAI"><p><span>after stopping </span> <span>tricyclics</span> <span>do not start</span> <span>moclobemide</span> <span>for at least 1 week</span>  </p></td><td></td></tr><tr><td><a href="bnf_int973-moxifloxacin.htm">Moxifloxacin</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>tricyclics</span> <span>given with</span> <span>moxifloxacin</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int615-moxonidine.htm">Moxonidine</a></td><td><p><span></span> <span>tricyclics</span> <span>possibly antagonise hypotensive effect of</span> <span>moxonidine</span> <span>(manufacturer of <span>moxonidine</span> advises avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int58-nefopam.htm">Nefopam</a></td><td><p><span>side-effects possibly increased when </span> <span>tricyclics</span> <span>given with</span> <span>nefopam</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int630-nicorandil.htm">Nicorandil</a></td><td><p><span></span> <span>tricyclics</span> <span>possibly enhance hypotensive effect of</span> <span>nicorandil</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int631-nitrates.htm">Nitrates</a></td><td><p><span></span> <span>tricyclics</span> <span>reduce effects of sublingual tablets of</span> <span>nitrates</span> <span>(failure to dissolve under tongue owing to dry mouth)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int711-noradrenaline-norepinephrine.htm">Noradrenaline (norepinephrine)</a></td><td class="cAI"><p><span>increased risk of hypertension and arrhythmias when </span> <span>tricyclics</span> <span>given with</span> <span>noradrenaline (norepinephrine)</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int636-oestrogens.htm">Oestrogens</a></td><td><p><span>antidepressant effect of </span> <span>tricyclics</span> <span>antagonised by</span> <span>oestrogens</span> <span>(but side-effects of <span>tricyclics</span>  possibly increased due to increased plasma concentration)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a></p></div></td></tr><tr><td><a href="bnf_int85-opioid-analgesics.htm">Opioid Analgesics</a></td><td><p><span>sedative effects possibly increased when </span> <span>tricyclics</span> <span>given with</span> <span>opioid analgesics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int808-pentamidine-isetionate.htm">Pentamidine Isetionate</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>tricyclics</span> <span>given with</span> <span>pentamidine isetionate</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td class="cAI"><p><span>metabolism of </span> <span>tricyclics</span> <span>possibly accelerated by</span> <span>phenobarbital</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int373-phenothiazines.htm">Phenothiazines</a></td><td><p><span>increased risk of antimuscarinic side-effects when </span> <span>tricyclics</span> <span>given with</span> <span>phenothiazines</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>tricyclics</span> <span>possibly reduced by</span> <span>phenytoin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int369-pimozide.htm">Pimozide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>tricyclics</span> <span>given with</span> <span>pimozide</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int125-propafenone.htm">Propafenone</a></td><td class="cAI"><p><span>increased risk of arrhythmias when </span> <span>tricyclics</span> <span>given with</span> <span>propafenone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1051-rasagiline.htm">Rasagiline</a></td><td class="cAI"><p><span>increased risk of CNS toxicity when </span> <span>tricyclics</span> <span>given with</span> <span>rasagiline</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Rasagiline is a MAO-B inhibitor</p></div></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>tricyclics</span> <span>possibly increased by</span> <span>ritonavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>tricyclics</span> <span>given with</span> <span>saquinavir</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int687-selegiline.htm">Selegiline</a></td><td class="cAI"><p><span>CNS toxicity reported when </span> <span>tricyclics</span> <span>given with</span> <span>selegiline</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Selegiline is a MAO-B inhibitor</p></div></td></tr><tr><td><a href="bnf_int1067-sodium-oxybate.htm">Sodium Oxybate</a></td><td><p><span>increased risk of side-effects when </span> <span>tricyclics</span> <span>given with</span> <span>sodium oxybate</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int455-sotalol.htm">Sotalol</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>tricyclics</span> <span>given with</span> <span>sotalol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int292-terbinafine.htm">Terbinafine</a></td><td><p><span>plasma concentration of </span> <span>tricyclics</span> <span>possibly increased by</span> <span>terbinafine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int935-thyroid-hormones.htm">Thyroid Hormones</a></td><td><p><span>effects of </span> <span>tricyclics</span> <span>possibly enhanced by</span> <span>thyroid hormones</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int106-tramadol.htm">Tramadol</a></td><td class="cAI"><p><span>increased risk of CNS toxicity when </span> <span>tricyclics</span> <span>given with</span> <span>tramadol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int467-verapamil.htm">Verapamil</a></td><td><p><span>plasma concentration of </span> <span>tricyclics</span> <span>possibly increased by</span> <span>verapamil</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Dosulepin</strong> belongs to <strong>Antidepressants</strong> and will have the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int937-artemether-with-lumefantrine.htm">Artemether with Lumefantrine</a></td><td class="cAI"><p><span>avoidance of </span> <span>antidepressants</span> <span>advised by manufacturer of</span> <span>artemether/lumefantrine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1009-atomoxetine.htm">Atomoxetine</a></td><td><p><span>possible increased risk of convulsions when </span> <span>antidepressants</span> <span>given with</span> <span>atomoxetine</span> <span></span>  </p></td><td></td></tr></tbody></table></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="bnf_int244-clomipramine.htm">Previous: Clomipramine</a> | <a class="top" href="bnf_int245-dosulepin.htm#">Top</a> | <a accesskey="]" href="bnf_int246-doxepin.htm">Next: Doxepin</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>